registHER: patient characteristics and time course of CNS metastases in patients with HER2-positive metastatic breast cancer.

被引：0
|
作者：
Yardley, D. A.
Kaufman, P. A.
Mayer, M.
Ulcickas, Yood M.
Tan-Chiu, E.
Brufsky, A. M.
Rugo, H. S.
Tripathy, D.
Brammer, M. G.
Paik, S.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Patient Advocate, New York, NY USA
[4] Yale Univ, Sch Med, EpiSource LLC, New Haven, CT USA
[5] Florida Canc Care, Tamarac, FL USA
[6] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA
[7] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[8] Univ Texas SW Med Ctr, Dallas, TX USA
[9] Genentech Inc, San Francisco, CA USA
[10] Natl Surg Breast & Bowel Project, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S263 / S264
页数：2
相关论文
共 50 条
  • [31] Brain metastases from HER2-positive breast cancer
    Susheela, Sridhar Papaiah
    Revannasiddaiah, Swaroop
    Madhusudhan, N.
    Basavalingaiah, Ajaikumar
    LANCET ONCOLOGY, 2013, 14 (01): : E3 - E3
  • [32] Updated Results of Tucatinib versus Placebo in Combination with Trastuzumab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB)
    Greil, R.
    Lin, U. N.
    Murthy, K. R.
    Abramson, V
    Anders, C.
    Bachelot, T.
    Bedard, L. P.
    Borges, V
    Cameron, D.
    Carey, L.
    Chien, J. A.
    Curigliano, G.
    DiGiovanna, P. M.
    Gelmon, K.
    Hortobagyi, G.
    Hurvitz, S.
    Krop, I
    Loi, S.
    Loibl, S.
    Mueller, V
    Oliveira, M.
    Paplomata, E.
    Pegram, M.
    Slamon, D.
    Zelnak, A.
    Ramos, J.
    Feng, W.
    Winer, E.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (04) : E4 - E5
  • [33] How we treat patients with metastatic HER2-positive breast cancer
    Nader-Marta, G.
    Martins-Branco, D.
    de Azambuja, E.
    ESMO OPEN, 2022, 7 (01)
  • [34] Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    Huang, Shang-Xiao
    Wang, Han-Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 252 - +
  • [35] Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China
    Qin, Tao
    Yuan, Zhong-Yu
    Peng, Rou-Jun
    Bai, Bing
    Zeng, Yin-Duo
    Shi, Yan-Xia
    Teng, Xiao-Yu
    Liu, Dong-Geng
    Wang, Shu-Sen
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (03) : 544 - 550
  • [36] Characteristics and survival of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
    Elvira Montoya-Restrepo, Maria
    Gomez Wolff, Luis Rodolfo
    Sanchez Jimenez, Astrid Viviana
    Garcia Garcia, Hector Ivan
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (03): : 112 - 118
  • [37] Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer
    Kowalczyk, Lidia
    Singer, Christian F.
    Staudigl, Christine
    Weber, Myriam
    Farr, Alex
    BREAST JOURNAL, 2017, 23 (03): : 352 - 353
  • [38] Therapy for HER2-Positive Metastatic Breast Cancer REPLY
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [39] Updates in Treatment of HER2-positive Metastatic Breast Cancer
    Avelino, Alzira R. M.
    Pulipati, Soumya
    Jamouss, Kevin
    Bhardwaj, Prarthna V.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (12) : 1471 - 1481
  • [40] The changing treatment of metastatic her2-positive breast cancer
    Mitsogianni, Maria
    Trontzas, Ioannis P.
    Gomatou, Georgia
    Ioannou, Stephanie
    Syrigos, Nikolaos K.
    Kotteas, Elias A.
    ONCOLOGY LETTERS, 2021, 21 (04)
12345